• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于检测药物相互作用并知晓暴露时间的理论模型。

A theoretical model for detecting drug interaction with awareness of timing of exposure.

作者信息

Shi Yi, Sun Anna, Yang Yuedi, Xu Jing, Li Justin, Eadon Michael, Su Jing, Zhang Pengyue

机构信息

Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA.

Park Tudor School, Indianapolis, IN, USA.

出版信息

Sci Rep. 2025 Apr 21;15(1):13693. doi: 10.1038/s41598-025-98528-5.

DOI:10.1038/s41598-025-98528-5
PMID:40258952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12012107/
Abstract

Drug-drug interaction-induced (DDI-induced) adverse drug event (ADE) is a significant public health burden. Risk of ADE can be related to timing of exposure (TOE) such as initiating two drugs concurrently or adding one drug to an existing drug. Thus, real-world data based DDI detection shall be expanded to investigate precise adverse DDI with a special awareness on TOE. We developed a Sensitive and Timing-awarE Model (STEM), which was able to optimize the probability of detection and control false positive rate for mining all two-drug combinations under case-crossover design, in particular for DDIs with TOE-dependent risk. We analyzed a large-scale US administrative claims data and conducted performance evaluation analyses. We identified signals of DDIs by using STEM, in particular for DDIs with TOE-dependent risk. We also observed that STEM identified significantly more signals than the conditional logistic regression model-based (CLRM-based) methods and the Benjamini-Hochberg procedure. In the performance evaluation, we found that STEM demonstrated proper false positive control and achieved a higher probability of detection compared to CLRM-based methods and the Benjamini-Hochberg procedure. STEM has a high probability to identify signals of DDIs in high-throughput DDI mining while controlling false positive rate, in particular for detecting signals of DDI with TOE-dependent risk.

摘要

药物相互作用诱导(DDI诱导)的药物不良事件(ADE)是一项重大的公共卫生负担。ADE的风险可能与暴露时间(TOE)有关,例如同时开始使用两种药物或在现有药物基础上添加一种药物。因此,应扩大基于真实世界数据的DDI检测,以调查精确的不良DDI,并特别关注TOE。我们开发了一种敏感且具有时间意识的模型(STEM),该模型能够在病例交叉设计下优化检测概率并控制假阳性率,以挖掘所有两种药物的组合,特别是对于具有TOE依赖性风险的DDI。我们分析了大规模的美国行政索赔数据并进行了性能评估分析。我们使用STEM识别了DDI信号,特别是对于具有TOE依赖性风险的DDI。我们还观察到,与基于条件逻辑回归模型(CLRM)的方法和Benjamini-Hochberg程序相比,STEM识别出的信号明显更多。在性能评估中,我们发现与基于CLRM的方法和Benjamini-Hochberg程序相比,STEM展示了适当的假阳性控制并实现了更高的检测概率。STEM在控制假阳性率的同时,有很高的概率在高通量DDI挖掘中识别DDI信号,特别是用于检测具有TOE依赖性风险的DDI信号。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e1e/12012107/c2436f990532/41598_2025_98528_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e1e/12012107/095c2a265d11/41598_2025_98528_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e1e/12012107/721d69e90687/41598_2025_98528_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e1e/12012107/5264ad9cac15/41598_2025_98528_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e1e/12012107/c2436f990532/41598_2025_98528_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e1e/12012107/095c2a265d11/41598_2025_98528_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e1e/12012107/721d69e90687/41598_2025_98528_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e1e/12012107/5264ad9cac15/41598_2025_98528_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e1e/12012107/c2436f990532/41598_2025_98528_Fig4_HTML.jpg

相似文献

1
A theoretical model for detecting drug interaction with awareness of timing of exposure.一种用于检测药物相互作用并知晓暴露时间的理论模型。
Sci Rep. 2025 Apr 21;15(1):13693. doi: 10.1038/s41598-025-98528-5.
2
Propensity score-adjusted three-component mixture model for drug-drug interaction data mining in FDA Adverse Event Reporting System.基于倾向评分调整的三组分混合模型在 FDA 不良事件报告系统中的药物相互作用数据挖掘。
Stat Med. 2020 Mar 30;39(7):996-1010. doi: 10.1002/sim.8457. Epub 2019 Dec 27.
3
Data-driven prediction of adverse drug reactions induced by drug-drug interactions.药物相互作用引起的药物不良反应的数据驱动预测。
BMC Pharmacol Toxicol. 2017 Jun 8;18(1):44. doi: 10.1186/s40360-017-0153-6.
4
A Precision Mixture Risk Model to Identify Adverse Drug Events in Subpopulations Using a Case-Crossover Design.基于病例交叉设计的精准混合风险模型,用于识别亚人群中的药物不良事件。
Stat Med. 2024 Nov 30;43(27):5088-5099. doi: 10.1002/sim.10216. Epub 2024 Sep 19.
5
Mining and visualizing high-order directional drug interaction effects using the FAERS database.利用 FAERS 数据库挖掘和可视化高阶定向药物相互作用效应。
BMC Med Inform Decis Mak. 2020 Mar 18;20(Suppl 2):50. doi: 10.1186/s12911-020-1053-z.
6
Adverse drug reactions caused by drug-drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items.药物相互作用导致心血管疾病患者药物不良反应:使用电子筛选数据库项目引入简单的预测工具。
Curr Med Res Opin. 2019 Nov;35(11):1873-1883. doi: 10.1080/03007995.2019.1647021. Epub 2019 Aug 26.
7
Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions.用于药物相互作用药物警戒的人工智能与数据挖掘
Clin Ther. 2023 Feb;45(2):117-133. doi: 10.1016/j.clinthera.2023.01.002. Epub 2023 Jan 31.
8
Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis.药物-药物相互作用相关的住院/就诊情况:系统评价和荟萃分析。
Pharmacoepidemiol Drug Saf. 2014 May;23(5):489-97. doi: 10.1002/pds.3592. Epub 2014 Mar 10.
9
Discovering Severe Adverse Reactions From Pharmacokinetic Drug-Drug Interactions Through Literature Analysis and Electronic Health Record Verification.通过文献分析和电子健康记录验证发现药代动力学药物相互作用引起的严重不良反应。
Clin Pharmacol Ther. 2025 Apr;117(4):1078-1087. doi: 10.1002/cpt.3500. Epub 2024 Nov 25.
10
Mining clinical text for signals of adverse drug-drug interactions.从临床文本中挖掘药物-药物不良相互作用信号。
J Am Med Inform Assoc. 2014 Mar-Apr;21(2):353-62. doi: 10.1136/amiajnl-2013-001612. Epub 2013 Oct 24.

引用本文的文献

1
Potential Drug Dose-Specific Adverse Three-Drug Combinations: A US Insurance Claims Data-Based Study.潜在的特定药物剂量的三联药物组合不良事件:一项基于美国保险理赔数据的研究。
Pharmacoepidemiol Drug Saf. 2025 Sep;34(9):e70199. doi: 10.1002/pds.70199.
2
Mapping the Global Research on Drug-Drug Interactions: A Multidecadal Evolution Through AI-Driven Terminology Standardization.绘制全球药物相互作用研究图谱:通过人工智能驱动的术语标准化实现的数十年演变
Bioengineering (Basel). 2025 Jul 19;12(7):783. doi: 10.3390/bioengineering12070783.
3
A trajectory-informed model for detecting drug-drug-host interaction from real-world data.

本文引用的文献

1
A Precision Mixture Risk Model to Identify Adverse Drug Events in Subpopulations Using a Case-Crossover Design.基于病例交叉设计的精准混合风险模型,用于识别亚人群中的药物不良事件。
Stat Med. 2024 Nov 30;43(27):5088-5099. doi: 10.1002/sim.10216. Epub 2024 Sep 19.
2
A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality.一项全国性队列研究比较了利尿剂和钙通道阻滞剂在肾素-血管紧张素系统抑制剂基础上对慢性肾脏病进展和死亡的疗效。
Kidney Int. 2023 Sep;104(3):542-551. doi: 10.1016/j.kint.2023.05.024. Epub 2023 Jun 16.
3
一种基于轨迹信息的模型,用于从真实世界数据中检测药物-药物-宿主相互作用。
J Biomed Inform. 2025 May 31;168:104859. doi: 10.1016/j.jbi.2025.104859.
Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock, and Hyperkalemia (BRASH) Syndrome: A Rising Entity of Severe Bradycardia.
心动过缓、肾衰竭、房室结阻滞、休克和高钾血症(BRASH)综合征:一种严重心动过缓的新兴病症。
Cureus. 2023 Feb 28;15(2):e35620. doi: 10.7759/cureus.35620. eCollection 2023 Feb.
4
Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions.用于探索药物-宿主因素相互作用的自发不良事件报告数据库的统计方法。
BMC Med Res Methodol. 2023 Mar 27;23(1):71. doi: 10.1186/s12874-023-01885-w.
5
Preincubation Time-Dependent, Long-Lasting Inhibition of Drug Transporters and Impact on the Prediction of Drug-Drug Interactions.预孵育时间依赖性、长时程的药物转运体抑制作用及其对药物相互作用预测的影响。
Drug Metab Dispos. 2023 Sep;51(9):1077-1088. doi: 10.1124/dmd.122.000970. Epub 2023 Feb 28.
6
Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England.比较临床试验人群代表性与真实世界人群:一项涵盖英国989种独特药物和286种病症的43895项试验及5685738名个体的外部有效性分析。
Lancet Healthy Longev. 2022 Oct;3(10):e674-e689. doi: 10.1016/S2666-7568(22)00186-6. Epub 2022 Sep 20.
7
A Computational Framework for Identifying Age Risks in Drug-Adverse Event Pairs.一种用于识别药物不良反应对中年龄风险的计算框架。
AMIA Jt Summits Transl Sci Proc. 2022 May 23;2022:524-533. eCollection 2022.
8
Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase.导致利伐沙班药物不良反应的药物相互作用:文献系统评价及VigiBase分析
J Pers Med. 2021 Mar 30;11(4):250. doi: 10.3390/jpm11040250.
9
Underrepresentation of the elderly in clinical trials, time for action.老年人在临床试验中的代表性不足,是采取行动的时候了。
Br J Clin Pharmacol. 2020 Oct;86(10):2014-2016. doi: 10.1111/bcp.14539. Epub 2020 Sep 9.
10
Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.长期使用 ACEI/ARB 与法国东北部转诊中心队列中重症 COVID-19 患者的严重肾功能障碍和急性肾损伤相关。
Clin Infect Dis. 2020 Dec 3;71(9):2447-2456. doi: 10.1093/cid/ciaa677.